TIDMOPTI
RNS Number : 5174I
OptiBiotix Health PLC
05 December 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Issue of Equity - Subscription
Appointment of Joint Broker
OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, cardiovascular disease,
diabetes and skincare, a nnounces that the Company has raised
GBP500,000 through the issue of 3,125,000 new ordinary shares of 2
pence each in the Company ("Ordinary Shares") at a price of 16
pence per share (the "Subscription") handled by Peterhouse Capital
Limited.
The net proceeds of the Subscription will be utilised to invest
in the Company's direct-to-consumer ("D2C") product model, in
particular to drive sales growth across the business and build
partnerships in the USA and for general working capital
purposes.
Appointment of Joint Broker
Separately, the Company announces the appointment of Peterhouse
Capital Limited as joint broker to the Company with immediate
effect.
Admission
Application will be made to the London Stock Exchange to admit
the 3,125,000 new Ordinary Shares to trading on AIM ("Admission").
Admission of the new Ordinary Shares is expected to occur on or
around 9 December 2022. The new Ordinary Shares will rank pari
passu with the existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 91,190,661 ordinary
shares of 2p each. The above figure may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company, under the Disclosure and
Transparency Rules.
Stephen O'Hara, CEO of OptiBiotix, commented: " I am pleased
with the interest shown from new and existing shareholders in this
fundraise which will support further company growth. The funds will
support an acceleration of our direct to consumer business, help
expand our US partner network, and launch our second generation
products into the market. These steps will help create shareholder
value and support OptiBiotix's position as a leader in the
microbiome field."
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc ( Joint Broker) Tel: 020 7397 8900
Callum Davidson
Michael Johnson / Russell Kerr (Sales)
Peterhouse Capital Limited (Joint Broker) Tel: 020 7220 9797
Duncan Vasey/ Lucy Williams
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identiÞed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements reßect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEZZMGZRFZGZZM
(END) Dow Jones Newswires
December 05, 2022 02:00 ET (07:00 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
OptiBiotix Health (AQSE:OPTI.GB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
